Non-Insulin Therapies for Diabetes Market Size, Share, Growth, Forecast 2030

Non-Insulin Therapies for Diabetes Industry Prospective:

The global non-insulin therapies for diabetes market size was worth around USD 21.1 billion in 2022 and is predicted to grow to around USD 32.3 billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.5% between 2023 and 2030.       

Request Free Sample   

Non-Insulin Therapies for Diabetes Market: Overview

Patients with type 2 diabetes who either lack enough insulin or can't adequately utilize the insulin they make typically receive non-insulin therapy. Non-insulin-based medications lower blood glucose levels and maintain optimum glycemic control by combining several activities. For instance, certain administrators (Sulfonylureas), while other experts (Biguanides) boost peripheral glucose uptake and decrease hepatic glucose yield, increase insulin release from pancreatic cells. On the other hand, several medications (alpha-glucosidase inhibitors) stop the small intestine from absorbing starch, and other treatments reduce post-meal sugar by obstructing a particular molecule.

Key Insights

• As per the analysis shared by our research analyst, the global Non-Insulin Therapies for Diabetes market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2023-2030).
• In terms of revenue, the global Non-Insulin Therapies for Diabetes market size was valued at around USD 21.1 billion in 2022 and is projected to reach USD 32.3 billion, by 2030.
• The increasing number of cases of diabetes across the globe is expected to drive the non-insulin therapies for diabetes market growth.
• Based on the drug class, the DPP-4 Inhibitors segment is expected to hold a significant market share over the forecast period.
• Based on the route of administration, the oral segment is expected to capture the largest market share over the forecast period.
• Based on the distribution channel, the hospital pharmacy is expected to dominate the market over the forecast period.
• Based on region, North America is expected to dominate the market over the forecast period.

Request Free Sample

Non-Insulin Therapies for Diabetes Market: Growth Drivers

The growing prevalence of type 2 diabetes drives market growth

Type 2 diabetes is becoming more and more common throughout the world, mostly as a result of sedentary lifestyles, poor diets, and obesity. The demand for non-insulin therapy is driven by the rise in the number of diabetics. For instance, the International Diabetes Federation (IDF) estimates that 536.6 million adults globally will have T2DM in 2021 and that by 2045, 783.2 million individuals will have the disease (12.2% of the population). In addition, as per the findings by the CDC, one in ten Americans, or more than 37 million people, have diabetes, and 90–95% of them have type 2 diabetes. The majority of persons with type 2 diabetes are over the age of 45, but it is becoming more common among kids, teenagers, and young adults. Thus, the aforementioned stats are expected to drive the global non-insulin therapies for diabetes market growth during the forecast period.

Non-Insulin Therapies for Diabetes Market: Restraints

High cost and complex treatments limit market expansion

Some non-insulin treatments can be rather expensive, especially when it comes to more recent and cutting-edge therapies. Some patients' access to these therapies may be restricted by cost considerations. Additionally, non-insulin treatments may include complicated treatment plans including several different medicines or pharmacological combinations. Some patients may stop taking their medications as a result of this intricacy. Thus, this is expected to limit the non-insulin therapies for diabetes industry growth during the forecast period.

Non-Insulin Therapies for Diabetes Market: Opportunities

Rising collaboration offers a lucrative opportunity for market growth

The increasing collaboration is expected to provide a lucrative opportunity for non-insulin therapies for diabetes market growth during the forecast period. In June 2023, the American Diabetes Association® (ADA) and Abbott established a partnership to better understand how diabetes technology, such as continuous glucose monitoring (CGM) devices, may assist individuals with diabetes in making educated choices regarding their diet and exercise. Dietary practices are essential for glucose regulation. However, recommending a general dietary strategy for diabetes control is exceedingly difficult due to individual differences in glycemic reactivity to the same meals. According to clinical research, maintaining constant blood glucose levels over time improves the clinical results for diabetics. An essential tool for managing diabetes is a CGM system, such as those produced by Abbott. They provide individualized, real-time information on the impact of diet and exercise on blood sugar levels. Thus, driving the market growth.

Non-Insulin Therapies for Diabetes Market: Challenges

Regulatory concerns might be a major challenge to market growth

New diabetic drugs may undergo a prolonged and expensive approval and regulatory procedure. Innovative non-insulin medicines may not enter the market as quickly as they would want due to regulatory obstacles. Thus, regulatory concerns might be a major challenging factor to the non-insulin therapies for diabetes market during the forecast period.

Non-Insulin Therapies for Diabetes Market: Segmentation

The global Non-Insulin Therapies for Diabetes industry is segmented based on drug class, route of administration, distribution channel, and region.

Based on the drug class, the global market is bifurcated into Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) Inhibitors. The DPP-4 Inhibitors segment is expected to hold a significant market share over the forecast period. DPP4 inhibitors are medicines that lower excessive blood sugar levels. They are frequently employed to manage type 2 diabetes. DPP4 inhibitors enhance blood glucose regulation and lower postprandial and fasting blood glucose levels without increasing body weight. Except when paired with other medications that can induce hypoglycemia, the risk of hypoglycemia when using DPP4 inhibitors is limited. DPP4 inhibitors block DPP4, an enzyme that breaks down incretin, from doing its job. When incretin is destroyed, type 2 diabetes may result because it helps the body create more insulin when it is needed and less glucose when it is not. These hormones are produced throughout the day, and eating causes their levels to rise. DPP4 inhibitors are therefore necessary to stabilize type 2 diabetes. As a result, their adoption is widespread. These elements will accelerate segment growth during the projection period.

Based on the route of administration, the non-insulin therapies for diabetes industry is bifurcated into oral and intramuscular. The oral segment is expected to capture the largest market share over the forecast period. The management of blood sugar levels requires oral non-insulin medicines for diabetes, which make up a sizable component of the market for those who treat the condition. The expansion of this segment of the diabetes market is primarily driven by improvements in drug formulation, patient preference for oral drugs, and a rise in the incidence of type 2 diabetes.

Based on the distribution channel, the global non-insulin therapies for diabetes market is bifurcated into retail pharmacy, hospital pharmacy, and online pharmacy. The hospital pharmacy is expected to dominate the market over the forecast period. Patients with diabetes who are hospital inpatients must receive their non-insulin prescriptions from hospital pharmacies. They make sure that patients get the proper drugs at the right times and in the right dosages. Moreover, when patients are administered non-insulin therapy for diabetes, hospital pharmacists are trained to monitor medication safety and manage any possible drug interactions, bad effects, or contraindications. Thus, this is expected to propel the market growth during the forecast period.

Non-Insulin Therapies for Diabetes Market: Report Scope

Non-Insulin Therapies For Diabetes Market: Regional Analysis

North America is expected to dominate the market growth over the forecast period

North America is expected to dominate the global non-insulin therapies for diabetes market during the forecast period. Hospitals, clinics, pharmacies, and other healthcare facilities are all present in the region, which has a strong healthcare infrastructure. This system helps with diabetes diagnosis and management, including the prescribing and delivery of non-insulin drugs. Moreover, one of the highest diabetes prevalence in the world is found in North America. The market for non-insulin therapy is mostly driven by the rise in the number of people with type 2 diabetes. For instance, according to the National Diabetes Statistics 2022 report, more than 37 million Americans of all ages (11.3 percent of the population) had diabetes in 2019, while 8.5 million adults (23.9 percent of adults with diabetes) were unaware of their condition.  The proportion of persons having diabetes climbed to 29.2% among those 65 years of age or older. Therefore, this is expected to propel the market expansion in the region.

Non-Insulin Therapies for Diabetes Market: Competitive Analysis

The global Non-Insulin Therapies for Diabetes market is dominated by players like:

• Pfizer
• Novo Nordisk
• AstraZeneca
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• Eli Lilly and Company
• GlaxoSmithKline
• F. Hoffmann-La Roche Ltd.
• Janssen Pharmaceuticals
• Merck and Company
• Novartis AG
• Sanofi Aventis
• Takeda Pharmaceuticals

The global Non-Insulin Therapies for Diabetes market is segmented as follows:

By Drug Class

• Biguanides
• Sulfonylureas
• Thiazolidinedione’s
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• GLP-1 Analogs
• Sodium-glucose co-transporter-2 (SGLT2) Inhibitors

By Route of Administration

• Oral
• Intramuscular

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa